The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 8, 2009, Pages 646-651

  Treliński, Jacek ^a   Tybura, Marzena ^a   Smolewski, Piotr ^a   Robak, Tadeusz ^a   Chojnowski, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Aspirin; Essential thrombocythemia; Hydroxyurea; P selectin; Platelet leukocyte conjugates; Thrombosis risk

Indexed keywords

ACETYLSALICYLIC ACID; CD11B ANTIGEN; GLYCOPROTEIN IB ALPHA; HYDROXYUREA; PADGEM PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL HEMORRHAGE; HUMAN; IN VIVO STUDY; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; LOW DRUG DOSE; MALE; MONOCYTE; NEUTROPHIL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTHEMIA; THROMBOGENESIS;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; CELL COMMUNICATION; FEMALE; HUMANS; HYDROXYUREA; LEUKOCYTES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEUTROPHILS; RISK ASSESSMENT; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS;

EID: 70449586835     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832f6c5b     Document Type: Article

References (39)

1. Rozman C, Giralt M, Feliu E, Rubio D, Corté s MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67:2658-2663.
2. Brodmann S, Passweg JR, Gratwohl A, Tichelli A, Skoda RC. Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol 2000; 79:312-318.
3. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128:275-290.
4. Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. Eur J Cancer Clin Oncol 1983; 19:1593-1599.
5. Balduini CL, Bertolino G, Noris P, Piletta GC. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clinical Pathol 1991; 95:82-86.
6. Manoharan A, Gemmell R, Brighton T, Dunkley S, Lopez K, Kyle P. Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. Br J Haematol 1999; 105:618-625.
7. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia:interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109:2310-2313.
8. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96:4261-4266.
9. Falanga A, Marchetti M, Barbui T, Smith CW. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 2005; 42:239-247. (Pubitemid 41400665)
10. Jensen MK, De Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001; 66:143-151.
11. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33:523-530. (Pubitemid 40592168)
12. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006; 91:169-175.
13. Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 2002; 108:139-145.
14. Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica 2008; 93:331-335.
15. Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 2008; 22:1494-1502.
16. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332:1132-1136.
17. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34:29-39.
18. Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost 1997; 78:617-621.
19. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8:556-562.
20. Vannucchi AM, Barbui T. Thrombocytosis and thrombosis. Hematol Am Soc Hematol Educ Program 2007; 2007:363-370.
21. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 81:159-166.
22. De Gaetano G, Cerletti C, Evangelista V. Recent advances in plateletpolymorphonuclear leukocyte interaction. Haemostasis 1999; 29:41-49.
23. Altieri DC, Morrissey JH, Edgington TS. Adhesive receptor MAC-1 coordinates the action of factor X on stimulated cells of monocyte and myeloid differentiation: an alternative initiation of the coagulation protease cascades. Proc Natl Acad Sci U S A 1988; 85:7462.
24. Jensen MK, De Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000; 110:116-124.
25. Frijns CJ, Kappelle LJ, Van Gijn J, Nieuwenhuis HK, Sixma JJ, Fijnheer R. Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke 1997; 28:2214-2218.
26. Vidal C, Spaulding C, Picard F, Schaison F, Melle J, Weber S, et al. Flow cytometry detection of platelet procoagulation activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation. Thromb Haemost 2001; 86:784-790.
27. Griesshammer M, Beneke H, Nussbaumer B, Grünewald M, Bangerter M, Bergmann L. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia. Thromb Res 1999; 96:191-196.
28. Harrison CR, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353:33-45.
29. Evangelista V, Manarini S, Rotondo S, Martelli N, Polischuk R, McGregor JL, et al. Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: evidence of adhesion cascade and cross talk between Pselectin and beta 2 integrin CD11b/CD18. Blood 1996; 88:4183-4194.
30. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992; 19:1-10.
31. Piccardoni P, Sideri R, Manarini S, Piccoli A, Martelli N, De Gaetano G, et al. Platelet/polymorphonuclear leukocyte adhesion: a new role for SRC kinases in MAC-1 adhesive function triggered by P-selectin. Blood 2001; 98:108-116.
32. Maugeri N, Giordano G, Petrilli MP, Fraticelli V, de Gaetano G, Cerletti C, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 2006; 4:2593-2598.
33. Van Genderen PJJ, Mulder PGH, Waleboer M, Van De Moesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of low-dose aspirin. Br J Haematol 1997; 97:179-184.
34. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23:2224-2232.
35. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al., GIMEMA CMD-Working Party. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008; 93:372-380.
36. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353:2373-2383.
37. Li N, Hu H, Hjemdahl P. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003; 111:165-170.
38. Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003; 73:232-240.
39. Cao YJ, Wang YM, Zhang J, Zeng YJ, Liu CF. The effects of antiplatelet agents on platelet-leukocyte aggregations in patients with acute cerebral infarction. J Thromb Thrombolysis 2009; 27:233-238.